Published in Cancer Res on May 25, 2010
Understanding the language of Lys36 methylation at histone H3. Nat Rev Mol Cell Biol (2012) 3.52
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol (2012) 3.20
The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSα. Cell (2013) 2.87
The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood (2010) 2.71
NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol Cell (2011) 2.27
Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. Radiology (2013) 2.21
Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat Genet (2014) 1.94
SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair. Oncogene (2015) 1.65
State of the science: an update on renal cell carcinoma. Mol Cancer Res (2012) 1.58
SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint. Elife (2014) 1.33
Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. Genome Res (2013) 1.31
Integrated analysis of germline and somatic variants in ovarian cancer. Nat Commun (2014) 1.31
Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet (2015) 1.24
Sinefungin derivatives as inhibitors and structure probes of protein lysine methyltransferase SETD2. J Am Chem Soc (2012) 1.17
The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. Cancer Med (2014) 1.16
FOXP3 orchestrates H4K16 acetylation and H3K4 trimethylation for activation of multiple genes by recruiting MOF and causing displacement of PLU-1. Mol Cell (2011) 1.14
Histone methyltransferase SETD2 coordinates FACT recruitment with nucleosome dynamics during transcription. Nucleic Acids Res (2013) 1.12
Lysine methylation of promoter-bound transcription factors and relevance to cancer. Cell Res (2010) 1.10
Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model. Nat Genet (2013) 1.04
BS69/ZMYND11 reads and connects histone H3.3 lysine 36 trimethylation-decorated chromatin to regulated pre-mRNA processing. Mol Cell (2014) 1.04
LncRNA HOTAIR promotes human liver cancer stem cell malignant growth through downregulation of SETD2. Oncotarget (2015) 1.03
Epigenetic regulation in RCC: opportunities for therapeutic intervention? Nat Rev Urol (2012) 0.99
Driver mutations of cancer epigenomes. Protein Cell (2014) 0.98
miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma. Oncotarget (2015) 0.93
Epigenomics of clear cell renal cell carcinoma: mechanisms and potential use in molecular pathology. Chin J Cancer Res (2016) 0.91
Pervasive transcription read-through promotes aberrant expression of oncogenes and RNA chimeras in renal carcinoma. Elife (2015) 0.90
Trimethylation of histone H3 lysine 36 by human methyltransferase PRDM9 protein. J Biol Chem (2014) 0.89
JARID1B promotes metastasis and epithelial-mesenchymal transition via PTEN/AKT signaling in hepatocellular carcinoma cells. Oncotarget (2015) 0.87
Radiogenomics of clear cell renal cell carcinoma: preliminary findings of The Cancer Genome Atlas-Renal Cell Carcinoma (TCGA-RCC) Imaging Research Group. Abdom Imaging (2015) 0.87
The role of epigenetics in kidney malignancies. Cent European J Urol (2015) 0.86
Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma. Cancer J (2013) 0.86
The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer. Cancer Genet (2015) 0.85
The role of components of the chromatin modification machinery in carcinogenesis of clear cell carcinoma of the ovary (Review). Oncol Lett (2011) 0.83
Histone H3 mutations--a special role for H3.3 in tumorigenesis? Chromosoma (2015) 0.83
Prognostic value of EZH2 expression and activity in renal cell carcinoma: a prospective study. PLoS One (2013) 0.82
Genetic alterations of chromosomes, p53 and p16 genes in low- and high-grade bladder cancer. Oncol Lett (2014) 0.82
Expression of histone methyltransferases as novel biomarkers for renal cell tumor diagnosis and prognostication. Epigenetics (2015) 0.82
Choosing the right cell line for renal cell cancer research. Mol Cancer (2016) 0.82
Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity. Mod Pathol (2016) 0.82
Manipulating the epigenome for the treatment of urological malignancies. Pharmacol Ther (2013) 0.81
Renal cell neoplasms contain shared tumor type-specific copy number variations. Am J Pathol (2012) 0.81
Genomic aberrations frequently alter chromatin regulatory genes in chordoma. Genes Chromosomes Cancer (2016) 0.80
Histone modifications: implications in renal cell carcinoma. Epigenomics (2013) 0.80
Tumor characterization and stratification by integrated molecular profiles reveals essential pan-cancer features. BMC Genomics (2015) 0.80
Decoding the histone code: Role of H3K36me3 in mismatch repair and implications for cancer susceptibility and therapy. Cancer Res (2013) 0.80
The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma. J Am Soc Nephrol (2016) 0.80
The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease. Nat Rev Nephrol (2015) 0.79
Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma. Oncotarget (2016) 0.79
SETD2: an epigenetic modifier with tumor suppressor functionality. Oncotarget (2016) 0.78
New insights and challenges in mismatch repair: getting over the chromatin hurdle. DNA Repair (Amst) (2014) 0.78
Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia. Leukemia (2016) 0.78
Associations between Blood and Urine Arsenic Concentrations and Global Levels of Post-Translational Histone Modifications in Bangladeshi Men and Women. Environ Health Perspect (2016) 0.77
Histone H3.3 and cancer: A potential reader connection. Proc Natl Acad Sci U S A (2014) 0.77
Genome-Wide Profiling of TRACK Kidneys Shows Similarity to the Human ccRCC Transcriptome. Mol Cancer Res (2015) 0.77
Predictive markers of efficacy for an angiopoietin-2 targeting therapeutic in xenograft models. PLoS One (2013) 0.77
Inhibitors of Protein Methyltransferases and Demethylases. Chem Rev (2017) 0.76
A PWWP Domain of Histone-Lysine N-Methyltransferase NSD2 Binds to Dimethylated Lys-36 of Histone H3 and Regulates NSD2 Function at Chromatin. J Biol Chem (2016) 0.76
Alterations in the rat serum proteome induced by prepubertal exposure to bisphenol a and genistein. J Proteome Res (2014) 0.76
The application of nonsense-mediated mRNA decay inhibition to the identification of breast cancer susceptibility genes. BMC Cancer (2012) 0.76
Medical treatment of renal cancer: new horizons. Br J Cancer (2016) 0.76
Marked for death: targeting epigenetic changes in cancer. Nat Rev Drug Discov (2017) 0.76
Identification of DNA Methylation-Independent Epigenetic Events Underlying Clear Cell Renal Cell Carcinoma. Cancer Res (2016) 0.76
Writing, erasing and reading histone lysine methylations. Exp Mol Med (2017) 0.75
Structure/Function Analysis of Recurrent Mutations in SETD2 Protein Reveals a Critical and Conserved Role for a SET Domain Residue in Maintaining Protein Stability and Histone H3 Lys-36 Trimethylation. J Biol Chem (2016) 0.75
Functional Studies on Primary Tubular Epithelial Cells Indicate a Tumor Suppressor Role of SETD2 in Clear Cell Renal Cell Carcinoma. Neoplasia (2016) 0.75
Dot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma. Oncotarget (2016) 0.75
Role of several histone lysine methyltransferases in tumor development. Biomed Rep (2016) 0.75
Sex-specific associations between one-carbon metabolism indices and posttranslational histone modifications in arsenic-exposed Bangladeshi adults. Cancer Epidemiol Biomarkers Prev (2016) 0.75
The epigenetic landscape of clear-cell renal cell carcinoma. J Kidney Cancer VHL (2015) 0.75
Prognostic value of cross-omics screening for kidney clear cell renal cancer survival. Biol Direct (2016) 0.75
Genetic and Chromosomal Aberrations and Their Clinical Significance in Renal Neoplasms. Biomed Res Int (2015) 0.75
Recognizing the Continuous Nature of Expression Heterogeneity and Clinical Outcomes in Clear Cell Renal Cell Carcinoma. Sci Rep (2017) 0.75
Reduced expression of SETD2 and SNX9 proteins in chemically induced mammary tumorigenesis in Wistar rats: a prognostic histological and proteomic study. Protoplasma (2016) 0.75
Probe the function of histone lysine 36 methylation using histone H3 lysine 36 to methionine mutant transgene in mammalian cells. Cell Cycle (2017) 0.75
Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet (2010) 13.70
Evidence based selection of housekeeping genes. PLoS One (2007) 7.90
Trans-eQTLs reveal that independent genetic variants associated with a complex phenotype converge on intermediate genes, with a major role for the HLA. PLoS Genet (2011) 3.65
Plakophilin-2 mutations are the major determinant of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation (2006) 3.44
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother (2008) 2.54
Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol (2009) 2.48
Pathological assessment of mismatch repair gene variants in Lynch syndrome: past, present, and future. Hum Mutat (2012) 2.32
Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet (2002) 2.17
Differential contributions of rare and common, coding and noncoding Ret mutations to multifactorial Hirschsprung disease liability. Am J Hum Genet (2010) 2.12
C. elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging. PLoS Genet (2008) 2.03
Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol (2005) 2.01
Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med (2009) 1.88
Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study. Lancet Oncol (2010) 1.84
In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med (2007) 1.79
Severe cardiac phenotype with right ventricular predominance in a large cohort of patients with a single missense mutation in the DES gene. Heart Rhythm (2009) 1.78
Mutation update on the CHD7 gene involved in CHARGE syndrome. Hum Mutat (2012) 1.74
Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol (2010) 1.70
Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma? Hum Pathol (2006) 1.70
Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer (2009) 1.70
Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet (2004) 1.66
The international dystrophic epidermolysis bullosa patient registry: an online database of dystrophic epidermolysis bullosa patients and their COL7A1 mutations. Hum Mutat (2011) 1.65
Left ventricular outflow tract obstruction: should cardiac screening be offered to first-degree relatives? Heart (2011) 1.63
Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med (2011) 1.62
Gene amplification as double minutes or homogeneously staining regions in solid tumors: origin and structure. Genome Res (2010) 1.62
BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene (2005) 1.62
Calibration of multiple in silico tools for predicting pathogenicity of mismatch repair gene missense substitutions. Hum Mutat (2012) 1.61
Nine patients with a microdeletion 15q11.2 between breakpoints 1 and 2 of the Prader-Willi critical region, possibly associated with behavioural disturbances. Eur J Med Genet (2009) 1.60
Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol (2009) 1.53
Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail (2012) 1.51
Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol Biomarkers Prev (2002) 1.50
Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas due to promoter substitution. Hum Mol Genet (2003) 1.47
Homozygous nonsense mutations in KIAA1279 are associated with malformations of the central and enteric nervous systems. Am J Hum Genet (2005) 1.47
Locus-specific databases and recommendations to strengthen their contribution to the classification of variants in cancer susceptibility genes. Hum Mutat (2008) 1.44
Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer (2009) 1.43
RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev (2006) 1.41
High yield of LMNA mutations in patients with dilated cardiomyopathy and/or conduction disease referred to cardiogenetics outpatient clinics. Am Heart J (2007) 1.38
A genetic variants database for arrhythmogenic right ventricular dysplasia/cardiomyopathy. Hum Mutat (2009) 1.38
Amplicon mapping and expression profiling identify the Fas-associated death domain gene as a new driver in the 11q13.3 amplicon in laryngeal/pharyngeal cancer. Clin Cancer Res (2007) 1.37
Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol (2003) 1.36
A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting. Hum Mutat (2006) 1.34
Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol (2003) 1.31
VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res (2010) 1.27
Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem (2004) 1.27
A database to support the interpretation of human mismatch repair gene variants. Hum Mutat (2008) 1.27
Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer (2009) 1.26
The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. J Clin Endocrinol Metab (2011) 1.25
Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecol Oncol (2005) 1.24
A high throughput experimental approach to identify miRNA targets in human cells. Nucleic Acids Res (2009) 1.24
89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med (2010) 1.23
Assessment of gene promoter hypermethylation for detection of cervical neoplasia. Int J Cancer (2006) 1.23
Current concepts in RET-related genetics, signaling and therapeutics. Trends Genet (2006) 1.23
FISH and array-CGH analysis of a complex chromosome 3 aberration suggests that loss of CNTN4 and CRBN contributes to mental retardation in 3pter deletions. Am J Med Genet A (2006) 1.19
Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol (2008) 1.19
Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol (2003) 1.17
Functional analysis helps to clarify the clinical importance of unclassified variants in DNA mismatch repair genes. Hum Mutat (2007) 1.16
Contribution of rare and common variants determine complex diseases-Hirschsprung disease as a model. Dev Biol (2013) 1.15
An oncological view on the blood-testis barrier. Lancet Oncol (2002) 1.15
Involvement of the TGF-beta and beta-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer. Clin Cancer Res (2011) 1.13
Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem (2007) 1.13
Identification of MOAG-4/SERF as a regulator of age-related proteotoxicity. Cell (2010) 1.12
Vulvar carcinoma. The price of less radical surgery. Cancer (2002) 1.12
Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours. J Pathol (2009) 1.11
Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients. J Hematol Oncol (2013) 1.09
Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism. J Biol Chem (2011) 1.09
Candidate driver genes in microsatellite-unstable colorectal cancer. Int J Cancer (2011) 1.08
Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol (2006) 1.08
Genomic aberrations in squamous cell lung carcinoma related to lymph node or distant metastasis. Lung Cancer (2009) 1.07
Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer. Oncogene (2005) 1.07
PMS2 involvement in patients suspected of Lynch syndrome. Genes Chromosomes Cancer (2009) 1.07
Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer (2012) 1.07
Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development. Hum Mutat (2012) 1.06
A novel classification system to predict the pathogenic effects of CHD7 missense variants in CHARGE syndrome. Hum Mutat (2012) 1.06
MiRNA profiling in B non-Hodgkin lymphoma: a MYC-related miRNA profile characterizes Burkitt lymphoma. Br J Haematol (2010) 1.05
Interphase fluorescence in situ hybridization for detection of 8q24/MYC breakpoints on routine histologic sections: validation in Burkitt lymphomas from three geographic regions. Genes Chromosomes Cancer (2004) 1.04
Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer. Clin Cancer Res (2009) 1.03
Genome-wide arrays: quality criteria and platforms to be used in routine diagnostics. Hum Mutat (2012) 1.03
The role of maternal-fetal cholesterol transport in early fetal life: current insights. Biol Reprod (2013) 1.03
Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component. Mod Pathol (2011) 1.01
The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer. Gynecol Oncol (2009) 1.00
An updated and upgraded L1CAM mutation database. Hum Mutat (2010) 0.99
Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model. Clin Cancer Res (2009) 0.99
Distinct transcriptional changes in donor kidneys upon brain death induction in rats: insights in the processes of brain death. Am J Transplant (2004) 0.99
Two mismatch repair gene mutations found in a colon cancer patient--which one is pathogenic? Hum Genet (2002) 0.99
CGH arrays compared for DNA isolated from formalin-fixed, paraffin-embedded material. Genes Chromosomes Cancer (2011) 0.99